相关实验视频
Updated: Jan 15, 2026

07:02
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
7.8K
神酶的抑制剂:一个双刃剑
Lucia Acampora1, Caterina Miro1, Annunziata Gaetana Cicatiello1
1Department of Clinical Medicine and Surgery, University of Naples "Federico II", 80131 Naples, Italy.
Frontiers in bioscience (Landmark edition)
|October 11, 2025
概括
代奥丁酶酶调节甲状腺激素 (TH) 代谢,并与癌症有关. 开发选择性代氧酶抑制剂对于癌症治疗至关重要,尽管在向酶特异性和瘤异质性方面存在挑战.
科学领域:
- 生物化学 生物化学
- 内分泌学 在内分泌学.
- 在瘤学瘤学.
背景情况:
- 代奥迪纳酶对甲状腺激素 (TH) 代谢至关重要,可以激活甲状腺素 (T4) 转化为三甲状腺素 (T3) 或使甲状腺激素 (THs) 失活.
- 代酶的失调与各种疾病有关,特别是癌症,它们会影响瘤的进展和攻击性.
- 目前存在的二胺酶抑制剂的数量有限,这给治疗开发带来了挑战.
研究的目的:
- 提供关于代酶抑制剂的当前知识的概述.
- 突出除氧酶抑制剂的潜力和局限性,特别是在癌症治疗的背景下.
- 确定未来的研究方向,以优化神酶抑制剂的开发.
主要方法:
- 关于二氧化酶及其抑制剂的文献综述.
- 对神酶在癌症生物学中的作用和治疗影响的分析.
- 讨论实现抑制剂酶和组织特异性的挑战.
主要成果:
- 代胺酶在癌症中起着双重作用,作为瘤中改变表达的瘤过程的调节者.
- 开发选择性代氧酶抑制剂面临的障碍是由于酶异质性和需要在健康组织中保持TH调节.
- 目前的抑制剂有限,在癌症中有效向这些酶方面仍然存在重大挑战.
结论:
- 代氧酶抑制剂显示出作为一种新型的癌症治疗药物的潜力.
- 未来的研究必须专注于识别强效抑制剂,改善输送,并优化疗法,以平衡疗效和最大限度地减少副作用.
- 解决瘤中二氧酶表达的空间和时间异质性是成功治疗策略的关键.
相关概念视频
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
1.9K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.9K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.1K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
488
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
488
Dipeptidyl Peptidase 4 Inhibitors
587
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
587
Heart Failure Drugs: Inotropic Agents
1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K
Therapeutic Index
6.6K
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
6.6K

